FAQ Frequently Asked Questions Quick answers to common questions about appointments, pharmacy support, and locations
The oral small-molecule inhibitor INCB001158 (CB-1158), targeting this axis, has entered first-inhuman phase I studies and has been explored in combination with PD-1 inhibitors, suggesting that relieving substrate depletion-driven immunosuppression is clinically feasible from a safety and pharmacodynamic perspective, although its therapeutic efficacy remains to be fully established (116)
SynZeal products are for analytical purpose only and not for human use
Dimensions: 8256 x 5504 px | 69.9 x 46.6 cm | 27.5 x 18.3 inches | 300dpi Date taken: 4 May 2022 Location: Naples, Florida, United States of America Available for Editorial use only
Over time, this results in a brighter, more even skin tone
Acta 1778 , 709716 (2008)